carefully before any decision is made with respect to the tender offer. Those materials and all other documents filed by, or caused
to be filed by, Novartis and Purchaser with the SEC will be available at no charge on the SEC’s website at www.sec.gov.
The Schedule TO Tender Offer Statement and related materials may be obtained for free under the “Investors – Financial
Data” section of Novartis website at https://www.novartis.com/investors/financial-data/sec-filings. The Schedule 14D-9 Solicitation/Recommendation
Statement and such other documents may be obtained for free from the Company under the “Investor Relations” section
of the Company’s website at http://investorrelations.adacap.com/.
Statement Regarding Forward-Looking Statements
release contains forward-looking statements. All statements, other than statements of historical facts, contained in this press
release, including statements regarding the Company's strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate,"
"believe," "estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could," "should,"
"continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain these identifying words. Forward-looking statements that appear in a number of places in this press release
include the Company's current expectation regarding future events and various matters, including expected timing of filings with
the FDA, approval dates and expansion of NETSPOT®. These forward-looking statements involve risks and uncertainties
that may cause actual results, events or developments to be materially different from any future results, events or developments
expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions,
the successful and timely completion of clinical studies, the timing of our submission of applications for regulatory approvals,
FDA and other regulatory approvals for our product candidates, the occurrence of side effects or serious adverse events caused
by or associated with our products and product candidates; our ability to procure adequate quantities of necessary supplies and
raw materials for USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide (Lutathera®) and
other chemical compounds acceptable for use in our manufacturing processes from our suppliers; our ability to organize timely
and safe delivery of our products or product candidates by third parties; any problems with the manufacture, quality or performance
of our products or product candidates; the rate and degree of market acceptance and the clinical utility of USAN: lutetium Lu
177 dotatate/INN: lutetium (177Lu) oxodotreotide (Lutathera®) and our other products or product candidates;
our estimates regarding the market opportunity for USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide
(Lutathera®), our other product candidates and our existing products; our anticipation that we will generate higher
sales as we diversify our products; our ability to implement our growth strategy including expansion in the US; our ability to
sustain and create additional sales, marketing and distribution capabilities; our intellectual property and licensing position;
legislation or regulation in countries where we sell our products that affect product pricing, taxation, reimbursement, access
or distribution channels; regulatory actions or litigation; and general economic, political, demographic and business conditions
in Europe, the US and elsewhere. Except as required by applicable securities laws, we undertake no obligation to publicly update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.